VXRT实时信号 | 通过Getagraph.com最大化利润

出售 118687 min ago

@ $1.235

发出时间: 13 Feb 2024 @ 04:35

回报率: -40.98%

上一信号: Feb 13 - 03:01

上一信号: 购买

回报率: 2.06 %

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform...

Stats
今日成交量	2.10M
平均成交量	1.69M
市值	128.90M
EPS	$0 ( 2024-05-02 )
下一个收益日期	( $-0.140 ) 2024-06-11
Last Dividend	$12.19 ( 2012-11-09 )
Next Dividend	$0 ( N/A )
P/E	-1.280
ATR14	$0.00200 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-28	Tucker Sean	Buy	0
2024-03-28	Tucker Sean	Sell	3 902	Common Stock
2024-03-28	Cummings James F.	Sell	3 292	Common Stock
2024-03-18	Tucker Sean	Buy	90 000	Common Stock
2024-03-18	Tucker Sean	Buy	410 000	Stock Option (right to buy)

INSIDER POWER
94.60
Last 95 transactions
Buy: 10 890 181 \| Sell: 279 805

音量相关性

長: 0.40 (neutral)

短: 0.42 (neutral)

Signal:(70.404) Neutral

Vaxart Inc 相关性

10 最正相关
LYEL	0.934
LYRA	0.93
BNIXU	0.929
TCRT	0.92
WISA	0.915
GROM	0.914
AFMD	0.914
ARQQ	0.914
GRNA	0.913
BNOX	0.912

10 最负相关
LRFC	-0.93
STAY	-0.928
GLLI	-0.907
IBEX	-0.905
OSMT	-0.904
XOMAO	-0.899
CHPM	-0.898
XOMAP	-0.898
BCOR	-0.895
MNKD	-0.893

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Vaxart Inc 相关性 - 货币/商品

0.35
( neutral )

-0.25
( neutral )

0.00
( neutral )

-0.62
( weak negative )

Vaxart Inc 财务报表

Annual	2023
营收:	$7.38M
毛利润:	$2.88M (39.02 %)
EPS:	$-0.570

FY	2023
营收:	$7.38M
毛利润:	$2.88M (39.02 %)
EPS:	$-0.570

FY	2022
营收:	$107 000
毛利润:	$-3.16M (-2 953.27 %)
EPS:	$-0.840

FY	2021
营收:	$892 000
毛利润:	$0.00 (0.00 %)
EPS:	$-0.580

Financial Reports:

No articles found.

Vaxart Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Vaxart Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$12.19	2012-11-09
Last Dividend	$12.19	2012-11-09
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$12.19	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-05)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2012	$12.19	9.77%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-14.41	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.898	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-1.085	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.32	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.11	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.53	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0994	-1.500	8.34	-10.00	[0 - 0.6]
interestCoverageTTM	-57.60	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.459	2.00	-0.153	-0.306	[0 - 30]
freeCashFlowPerShareTTM	-0.471	2.00	-0.236	-0.471	[0 - 20]
debtEquityRatioTTM	0.158	-1.500	9.37	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.196	1.000	-0.0722	-0.0722	[0.2 - 0.8]
operatingProfitMarginTTM	-14.56	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-7.72	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.0623	0.800	-2.92	-2.33	[0.5 - 2]
Total Score				-1.818

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-1.356	1.000	-0.238	0	[1 - 100]
returnOnEquityTTM	-1.085	2.50	-8.46	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.471	2.00	-0.157	-0.471	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.459	2.00	-0.153	-0.306	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.00907	1.500	-3.27	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-12.31	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.58

Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.